Wanhuida Intellectual Property
Sponsored
Sponsored
-
Sponsored by Wanhuida Intellectual PropertyHonghui Hu of Wanhuida Intellectual Property examines three CNIPA invalidation decisions that provide valuable insights into how Swiss‑type claims are interpreted in China, with claim wording, efficacy, and prosecution strategy of critical importance -
Sponsored by Wanhuida Intellectual PropertyPaul Ranjard, Huang Hui, and Zhu Zhigang of Wanhuida Intellectual Property explain the proposed amendments to China’s Trademark Law, their ramifications, and the persisting issue surrounding the ‘right to use’
-
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu and Jicheng Yang of Wanhuida Intellectual Property analyse an invalidation decision that addresses how dosage and administration features affect the inventiveness assessment of pharmaceutical use claims in China
-
Sponsored by Wanhuida Intellectual PropertyYue Guan of Wanhuida Intellectual Property explains how the CNIPA’s rulings on mirogabalin besylate tablets highlight the importance of formulation patent drafting and claim amendments in China’s drug patent landscape
-
Sponsored by Wanhuida Intellectual PropertyXiaoping Wu of Wanhuida Intellectual Property explains how the CNIPA’s recent invalidation of a sustained-release patent illustrates key considerations in assessing inventive step for pharmaceutical formulation patents
-
Sponsored by Wanhuida Intellectual PropertyMinnan (Miranda) Xie of Wanhuida Intellectual Property analyses how China’s patent authorities and courts assess second medical use inventions, with key CNIPA decisions clarifying the treatment of dosage regimens and patient subgroups in novelty determinations
